Jacc: Cardiooncology最新文献

{"title":"A Clinically Applicable Conversion Formula Between NT-proBNP and BNP in Light-Chain Amyloidosis","authors":"Eli Muchtar MD, Allan S. Jaffe MD, Andrew Staron MD, Vaishali Sanchorawala MD, Heather Landau MD, Oren Pasvolsky MD, Rajshekhar Chakraborty MD, Suzanne Lentzsch MD, PhD, Morie A. Gertz MD, Angela Dispenzieri MD","doi":"10.1016/j.jaccao.2026.06.001","DOIUrl":"10.1016/j.jaccao.2026.06.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 437-439"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S2666-0873(26)00268-1","DOIUrl":"10.1016/S2666-0873(26)00268-1","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages I-CXIV"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148776057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular-Kidney-Metabolic Syndrome Staging and Cancer Risk","authors":"Xixi Xiao MD,&nbsp;Jiayong Li MD, PhD,&nbsp;Yu Ning MD, PhD,&nbsp;Yunyao Yang MD, PhD,&nbsp;Zhen Ou BM,&nbsp;Bin Dong MD, PhD,&nbsp;Yugang Dong MD, PhD,&nbsp;Yi Li MD, PhD,&nbsp;Chen Liu MD, PhD,&nbsp;Yilong Wang MD, PhD,&nbsp;Ruicong Xue MD, PhD","doi":"10.1016/j.jaccao.2026.05.012","DOIUrl":"10.1016/j.jaccao.2026.05.012","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular-kidney-metabolic (CKM) syndrome is an emerging integrative framework and a critical determinant of overall disease risk; however, its relationship with cancer risk and underlying mechanisms remains poorly understood.</div></div><div><h3>Objectives</h3><div>This study sought to investigate the association between CKM staging and incident cancer and elucidate mediators underlying this association, thereby uncovering pathways and potential targets for risk mitigation based on multiomics analysis.</div></div><div><h3>Methods</h3><div>UK Biobank participants were categorized into CKM stages 0 to 4 according to the American Heart Association staging framework based on International Classification of Diseases, 10th Revision codes. Cox regression was conducted to evaluate associations between CKM staging and overall cancer incidence. Proteomic and metabolomic mediators linking adjacent stages and cancer were identified using Cox regression, logistic regression, and mediation analysis and underwent Gene Ontology enrichment and interaction network analyses.</div></div><div><h3>Results</h3><div>Overall cancer risk increased stepwise from CKM stages 1 to 3, with slight attenuation but persistent elevation in stage 4. Stage-specific mediators and mechanisms were identified: leukocyte/lymphocyte activation and cell-cell adhesion in stage 1; T cell–related immunity and emerging immune tolerance induction in stage 2; emerging natural killer (NK) cell tolerance induction and respiratory burst involved in the inflammatory response in stage 3; and dominant NK cell tolerance induction and tissue-resident chronic pathology in stage 4. Dominant metabolomic mediation evolved from high-density lipoproteins (HDLs) and triglyceride-rich lipoproteins (TRLs) to low-density lipoproteins (LDLs). Protein-metabolite interaction networks revealed distinct profiles for each stage, including angiopoietin-like protein 1/HDL and asialoglycoprotein receptor 1/TRL interactions in early stages and phospholipid transfer protein/HDL, apolipoprotein M/LDL, and fibroblast growth factor–binding protein 1/intermediate-density lipoprotein/LDL correlations in advanced stages.</div></div><div><h3>Conclusions</h3><div>CKM staging is associated with incremental cancer risk and stage-specific immune-metabolic pathways, highlighting potential prevention targets.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 395-411"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer","authors":"Heather Moore PharmD,&nbsp;Laura A. Huppert MD,&nbsp;Javid J. Moslehi MD,&nbsp;Eric H. Yang MD,&nbsp;Sarah Hatcher MPH,&nbsp;Alexandra Thomas MD","doi":"10.1016/j.jaccao.2026.07.006","DOIUrl":"10.1016/j.jaccao.2026.07.006","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 357-363"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148776061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Quest for a Safer Use of Anthracyclines Continues","authors":"Alberto A. Gabizon MD, PhD,&nbsp;Joshua E. Levenson MD","doi":"10.1016/j.jaccao.2026.07.002","DOIUrl":"10.1016/j.jaccao.2026.07.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 376-377"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148776055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Divergent Effects of GnRH Agonist and GnRH Antagonist Treatment on Platelet Activity and Transcriptome","authors":"Antonia Beitzen-Heineke MD,&nbsp;Matthew Siskin MD,&nbsp;Matthew Muller MS,&nbsp;Anshini Bhatt MBBS, MPH,&nbsp;Kathryn C. Hafertepe BA,&nbsp;Yuhe Xia MS,&nbsp;Minas Economides MD,&nbsp;David R. Wise MD, PhD,&nbsp;Jeffrey S. Berger MD","doi":"10.1016/j.jaccao.2026.07.007","DOIUrl":"10.1016/j.jaccao.2026.07.007","url":null,"abstract":"<div><h3>Background</h3><div>Prostate cancer is associated with increased cardiovascular risk. Among androgen deprivation therapy (ADT) modalities, the gonadotropin-releasing hormone (GnRH) antagonist relugolix appears to confer a lower risk for cardiovascular events than the GnRH agonist leuprolide.</div></div><div><h3>Objectives</h3><div>The aim of this prospective study was to investigate the impact of relugolix and leuprolide on platelet phenotype.</div></div><div><h3>Methods</h3><div>Patients with prostate cancer initiating first-line ADT were prospectively enrolled. Blood samples were collected at baseline and 8 ± 4 weeks after treatment initiation. Platelet activation was assessed using flow cytometry (P-selectin, PAC-1, CD40, CD40L, and monocyte-platelet aggregates). Platelet RNA sequencing was performed to characterize treatment-associated transcriptomic changes.</div></div><div><h3>Results</h3><div>Compared with healthy control subjects, patients (n = 69) exhibited elevated P-selectin expression and enrichment of thromboinflammatory pathways. During leuprolide treatment (n = 40), PAC-1 expression increased compared with baseline in response to epinephrine, thrombin, adenosine diphosphate (ADP) and arachidonic acid (AA), while P-selectin increased in response to epinephrine and was higher with ADP and AA, though not statistically different. In contrast, during relugolix treatment (n = 29), AA-induced P-selectin expression and CD40 decreased. Platelet RNA sequencing in relugolix-treated patients demonstrated down-regulation of pathways associated with platelet activation and aggregation. Finally, leuprolide-treated patients on aspirin (n = 6) did not exhibit increased AA-induced platelet activation and in vitro P2Y₁₂ inhibition of patient-derived platelets attenuated activation induced by epinephrine, ADP, and AA.</div></div><div><h3>Conclusions</h3><div>Prostate cancer is associated with heightened platelet activation and thromboinflammatory signaling. Treatment with leuprolide, but not relugolix, was associated with further augmented platelet activity. These findings support further studies to clarify links with platelet-mediated cardiovascular risk and the potential role of platelet-targeted strategies.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 415-427"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148776058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic Risk Scores for Cardiovascular Risk Prediction in Breast Cancer Survivors","authors":"Anirudh Govind MBBS","doi":"10.1016/j.jaccao.2026.02.005","DOIUrl":"10.1016/j.jaccao.2026.02.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 443-444"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statin Use Attenuates Leuprolide-Associated Coronary Atherosclerosis Progression","authors":"Adithya K. Yadalam MD, MSc,&nbsp;Chang Liu PhD, MPH,&nbsp;Marly van Assen PhD,&nbsp;Nikhil T. Sebastian MD,&nbsp;Vishal R. Dhere MD,&nbsp;Bruce W. Hershatter MD,&nbsp;Pretesh R. Patel MD,&nbsp;Ashesh B. Jani MD,&nbsp;Carlo N. De Cecco MD, PhD,&nbsp;Stephanie M. Cantu MD,&nbsp;Anant Mandawat MD,&nbsp;Sagar A. Patel MD","doi":"10.1016/j.jaccao.2026.07.001","DOIUrl":"10.1016/j.jaccao.2026.07.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 440-442"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148776176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cardiometabolic-to-Cancer Axis","authors":"Adithya K. Yadalam MD, MSc,&nbsp;Yan V. Sun PhD","doi":"10.1016/j.jaccao.2026.06.004","DOIUrl":"10.1016/j.jaccao.2026.06.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 412-414"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148770022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemoglobin Decline After Oral Anticoagulation Initiation and Subsequent Cancer Detection in Patients With Atrial Fibrillation","authors":"Pil-Sung Yang MD,&nbsp;Jee Hyuk Byun MD,&nbsp;Hanjin Park MD,&nbsp;Daehoon Kim MD,&nbsp;Dongseon Kang MD,&nbsp;Young Shin Lee MD,&nbsp;Min Kim MD,&nbsp;Hong-Ju Kim MD,&nbsp;Han-Joon Bae MD,&nbsp;Jung-Hoon Sung MD,&nbsp;Boyoung Joung MD","doi":"10.1016/j.jaccao.2026.07.005","DOIUrl":"10.1016/j.jaccao.2026.07.005","url":null,"abstract":"<div><h3>Background</h3><div>Previous studies evaluating cancer risk during oral anticoagulation (OAC) have focused on overt bleeding events, whereas the significance of hemoglobin (Hb) decline in the absence of clinically overt bleeding events after OAC initiation has not been evaluated.</div></div><div><h3>Objectives</h3><div>The purpose of this study was to evaluate the association between Hb decline after OAC initiation in the absence of clinically overt bleeding events and subsequent cancer risk in patients with atrial fibrillation (AF).</div></div><div><h3>Methods</h3><div>Using the Korean National Health Insurance Service database linked to serial health examinations, 6,789 patients with AF were identified who underwent 2 examinations within 1 year before and after OAC initiation. Patients with prior cancer, end-stage renal disease, overt bleeding, or early OAC discontinuation were excluded. Patients were classified by Hb change (Hb decrease ≥2 g/dL vs no significant decrease). The primary outcome was incident cancer; secondary outcomes included site-specific cancers, all-cause mortality, thromboembolic events, and bleeding outcomes.</div></div><div><h3>Results</h3><div>During a median follow-up period of 10.6 months, patients with Hb decreases ≥2 g/dL had a higher incidence of overall cancer than those without (6.7 vs 4.3 per 100 person-years; adjusted HR: 1.42; 95% CI: 1.10-1.97). The association was particularly evident for gastrointestinal cancers (adjusted HR: 1.78; 95% CI: 1.12-2.83). Cancer risk associated with Hb declines was greater in older patients, those with chronic kidney disease, and those receiving antiplatelet therapy (<em>P</em> for interaction &lt; 0.05). Hb decline was also associated with higher all-cause mortality and major bleeding, with no differences in stroke.</div></div><div><h3>Conclusions</h3><div>In patients with AF initiating OAC, Hb decline ≥2 g/dL in the absence of clinically overt bleeding events is associated with increased cancer risk, particularly gastrointestinal malignancy, and higher mortality.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 4","pages":"Pages 378-391"},"PeriodicalIF":15.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148776060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}